ArticleSAGE open medical case reports2026
Purification and antibody-free ex-vivo expansion of peripheral blood-derived autologous natural killer cells: A Malaysian case series on patient safety and tolerability.
Article in SAGE open medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer cells are the most researched and employed cells for immunotherapy, which have expanded from autologous immune-enhanced therapies to genetically enhanced cell therapies such as chimeric antigen receptors natural killer cells. The present clinical case study aims to analyze and evaluate the safety and tolerability of ex-vivo expanded autologous natural killer cells via an in-house developed culture protocol. The novel, cultivation protocol enables high-yield and pure natural killer cell batches free of antibody usage, prior natural killer cell purification, or any magnetic-bead labeling, resulting in a fully human compatible cell expansion process. In this report, a total of nine patients were clinically infused with the in-house cultured natural killer cells and were monitored pre- and postinfusion for haematological parameters, liver function profile, hypersensitivity, inflammatory markers as well as pretumor markers to assess for the possibilities of natural killer cell-induced or any dose-dependent toxic/adverse reactions. The outcomes indicate that the patient infused with natural killer cells demonstrates good level of clinical safety with no signs of hepatotoxicity, hypersensitivity, inflammation, or any flares of preliminary tumor markers. The study provides supportive evidence of the clinical tolerance of autologous-derived natural killer cells cultured via the in-house protocol on patients in Malaysia and establishes a baseline for future clinical studies with a wider range of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.